MUMBAI, India, Sept. 28 -- Intellectual Property India has published a patent application (202611100238 A) filed by Upes on August 19, 2026, for Method For Preparing Hyaluronic Acid-Mediated Chitosan-Coated Mogroside-V-Melphalan Nanoconjugates For Cd44-Targeted Ovarian Cancer Therapy.
Inventors include Meghna Patial; Jyoti Rajput; Dr. Dhruv Kumar; and Dr. Vineet Kumar.
The application for the patent was published on September 25, 2026, under issue no. 39/2026.
Abstract: The present invention discloses a method (100) for preparing a hyaluronic acid mediated chitosan-coated Mogroside-V-Melphalan nanoconjugate for CD44-targeted ovarian cancer therapy. The method comprises preparing an organic phase comprising 10 mg of a Mogroside-V-Melphalan conjugate and 20 mg of native Mogroside-V dissolved in 2 mL of 70% (v/v) ethanol, followed by precision-controlled nanoprecipitation into 5 mL of an aqueous phase under ultrasonication to form a stabilized anionic Mogroside-V nanocore at pH 3. The nanocore is sequentially coated with 7 mL of 0.1% (w/v) chitosan at pH 4.5 and 14 mL of 0.05% (w/v) hyaluronic acid at pH 5.5 through electrostatic self-assembly to form a multilayered nanoconjugate. A final stabilization protocol comprising 10 cycles of ultrasonication produces a water-dispersible nanoconjugate, wherein the hyaluronic acid outer layer facilitates CD44 receptor-mediated targeting, the chitosan layer provides electrostatic stabilization, and the self-assembled Mogroside-V nanocore encapsulates the Mogroside-V-Melphalan conjugate for controlled release. FIG. 1 and 2
Disclaimer: Curated by HT Syndication.
